Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

NCT04315480 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER

Sponsor class

Conditions

SARS Pneumonia

Interventions

DRUG: Tocilizumab

Sponsor

Università Politecnica delle Marche

Collaborators

[object Object]